Elevated Signals Launches New Planning & Scheduling Module to Drive Profitable, Scalable Production
Our new module replaces these disconnected tools with a smarter, integrated system that brings structure to the chaos, helping manufacturers stay aligned, agile, and ahead of demand
The new module provides teams with agility through a drag-and-drop interface that automatically adjusts all related steps in the production plan. This enables them to accurately model capacity, avoid over- or underproduction, and respond faster to demand, cutting delays, reducing labour costs, and maximizing throughput.
Designed for regulated industries such as cannabis, nutraceuticals, food, and beverage, Elevated Signals brings all production data, including inventory, QA, work orders, and planning, into one flexible system. With everything in one place, manufacturers can easily trace batches, generate GMP-compliant records, and be audit-ready without the last-minute scramble. No more stitching together spreadsheets, calendars, and disconnected tools. Teams have instant clarity and can focus on production, not tracking down data.
'Factory managers need to hit production targets reliably and predictably, but most are still relying on spreadsheets and whiteboards to plan their operations,' said Amar Singh, CEO and co-founder of Elevated Signals. 'That leads to missed deadlines, team stress, inventory issues, and ultimately missing profitability and revenue goals. Our new module replaces these tools with a smarter, integrated system that brings structure to the chaos - helping manufacturers stay aligned, agile, and ahead of demand.'
'We've been using a tangle of spreadsheets to manage our production plans,' said Paul Brownfield, General Manager, QAP, Organnicraft Production Inc. 'Elevated Signals' Planning & Scheduling module will bring that whole process into one clear, interactive view. It'll ensure our plans are up-to-date, easy to edit, much more resilient, making team coordination effortless - especially when things change last minute.'
With the Planning & Scheduling module, teams can:
Connect planning directly to BOMs, inventory levels, SKUs, batches, work orders, QA requirements, and labour needs
Easily model and see plans in calendar or Gantt-style views
Create reusable templates for core workflows for greater efficiency
Schedule from ship dates or start dates, with built-in buffer logic
Looking ahead, this launch is just the beginning. Upcoming features like forecasting, costing, and AI insights will give manufacturers even greater control over performance and profit.
About Elevated Signals
Elevated Signals builds manufacturing operations software for regulated industries, including cannabis, nutraceuticals, food, and beverage. Its GMP-ready platform connects inventory, quality & compliance, planning, and costing into one easy-to-use system, empowering teams to plan smarter, act faster, and scale with confidence. Learn more at elevatedsignals.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
OPM Announces Its 2025 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its financial results for the first half of 2025, as approved by the Board of Directors on July 31, 2025. Philippe GENNE, Chairman and CEO of Oncodesign Precision Medicine, comments: "To date, it remains impossible to raise funds on Euronext for a biotechnology company that needs to conduct clinical proof-of-concept trials. As a result, our hopes for revenue and therefore cash availability rest primarily on discussions with potential buyers of our assets. The various cost-cutting measures we have taken since the beginning of this year are enabling us to continue these discussions over time, and the last quarter will be crucial in this regard." Karine LIGNEL, Managing Director and COO of Oncodesign Precision Medicine adds: "In a very difficult financial environment, we have taken management decisions that have enabled us to significantly reduce our expenses and thus extend our cash flow horizon as much as possible. We have also set up an equity financing line to deal with market uncertainties. Nevertheless, the situation remains complicated, and we are making every effort to secure a partnership for one of our assets." Key financial data A cost reduction program was implemented in the first half of 2025: Negotiations were held with the banks and BPI that granted the loan, resulting in a six-month deferral of principal repayments starting in April 2025 Expenses were reduced through The layoff of five employees in early 2025 A 50% reduction in the compensation of non-salaried corporate officers A freeze on salaries and bonus payments for the 2024 fiscal year A reduction in spending on non-priority programs. In terms of cash flow, rather than from an accounting perspective, this results in a reduction in payroll costs of €242k in the first half of 2025 and a projected reduction of €440k in the second half of this year. The reduction in expenditure is particularly significant for the item 'subcontracting and fees,' which will fall from €2,900k in the first half of 2024 to €1,773k in the first half of 2025. R&D expenses amounted to €1.74 million in the first half of 2025, compared with €3.61 million in the same period last year, as the company focused its efforts on the clinical development of OPM-101. Reintegration, in close collaboration with Servier, of all OPM-201 data and product stocks The most significant financial item in the first half of 2025 is the reintegration, as provided for in the partnership agreement, of the stock of OPM-201 GMP material produced by Servier. As this reintegration is being carried out without financial competing, OPM has called upon an external expert to determine fair value for these stocks. This expert carried out three different valuations to arrive at this fair value. A summary of these valuations is shown in the table below: The expert concluded that the fair value of these inventories falls within a range of €13 million to €16.2 million. OPM used the lower end of this range. OPM's revenue for the first half of 2025 was €0.1 million, the same as in the first half of 2024. Other income mainly consists of subsidies amounting to €0.3 million and €0.3 million in provision reversals. OPM's financial result was (€0.26) million, compared with (€0.1) million in the same period last year, mainly due to interest on outstanding loans and financial income from cash investments. OPM recorded €0.4 million in R&D tax credits in the first half of 2025, down 52% compared to last year. The amount of R&D tax credits was reduced by the amount of public aid, the R&D expenditure base decreased, and the rules for collecting R&D tax credits changed (exclusion of technology watch patents, etc.). OPM's half-year net income thus stands at €9,846k, due to the integration of OPM-201 inventories at an estimated value of €13m. Cash position of €2.5m at June 30, 2025 As of June 30, 2025, OPM had cash reserves of €2.5 million, before receiving the Research Tax Credit, compared to €9.6 million (including the Research Tax Credit) as of June 30, 2024. The Research Tax Credit, amounting to €1.1 million, was received in July 2025. OPM has access to a maximum €5 million equity financing facility, which it has not yet used. The Company is in discussions with financial and pharmaceutical partners with the goal of signing a partnership agreement or raising funds. 2025 perspectives OPM has submitted its Phase 1b/2a protocol for the REVERT study evaluating OPM-101 in patients with advanced melanoma resistant to anti-PD1 and is awaiting a response from Swiss ethics institutions. The first patient is expected to be enrolled by the end of 2025. Work on radioligands is continuing as part of the COMETE project. Partnership prospects or transfer mainly focus on the two most advanced molecules to date (OPM-101 and OPM-201). OPM's goal is to license or transfer OPM-101 at the end of Phase 2a to a pharmaceutical partner who will complete its development and commercialization. While we do not anticipate licensing or sales before the end of this phase in 2027, we are considering the possibility of a pharmaceutical partner taking a licensing option with the payment of an exclusivity fee, giving them first refusal on the results. For OPM-201, the objective is to find a partnership similar to the one we found with Servier in 2019 or a buyer. Availability of the 2025 half-year financial report The 2025 half-year financial report will be available on the company's website, within the legal deadline, before October 31, 2025. About Oncodesign Precision Medicine (OPM) Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine, dedicated to discovering treatments for resistant and metastatic cancers. OPM currently has two kinase inhibitors in clinical phase: OPM-101, intended for the treatment of chronic immuno-inflammatory digestive diseases and immuno-oncology, has demonstrated a significant therapeutic margin and absence of toxicity in its phase I healthy volunteers, with the start of phase 1b/2a in Oncology scheduled for early 2025. OPM-201, initially licensed to Servier and intended for the treatment of Parkinson's disease, completed its phase I trial in healthy volunteers at the end of 2024, and was reintegrated into OPM's portfolio. Both molecules come from the Nanocyclix ® technology platform, which enables the design and selection of small, highly effective and selective macrocyclic kinase inhibitors. We now have 12,000 molecules in our library and will be using AI to accelerate the discovery of drug candidates while reducing the cost of this phase. OPM's other two technology platforms are: OncoSNIPER, for the selection of therapeutic targets using artificial intelligence, on which we have a partnership with Servier for the search for targets in pancreatic cancer, PROMETHE ® for the design and selection of radiolabeled biological molecules for systemic radiotherapy, on which we are currently discussing partnerships with vectorization manufacturers. OPM, co-founded by Philippe Genne, Jan Hoflack and Karine Lignel, is based in Dijon, at the heart of the university and hospital cluster, and employs 14 people. More info at: Forward-looking statements This document contains forward-looking statements and estimates with respect to the financial condition, results of operations, strategy, plans and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates can be identified by the use of words such as, without limitation, "believes", "anticipates", "expects", "projects", "plans", "seeks", "estimates", "may", "will" and "continue" and other similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were believed to be reasonable when they were made but which may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the Company's control. Consequently, the actual results, financial conditions, performance or achievements of the Company, or industry results, may differ materially from future results, performance or achievements as expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, the forward-looking statements, forecasts and estimates speak only as of the date of publication of this document. The Company disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which these statements, forecasts or estimates are based, except as required by French law.
Business Wire
18 minutes ago
- Business Wire
Game Developers Conference Appoints Games Industry Luminary Mark DeLoura Executive Director of Innovation & Growth
SAN FRANCISCO--(BUSINESS WIRE)--The Game Developers Conference (GDC), the world's largest and longest-running event serving professionals dedicated to the art and science of making games, has appointed longtime GDC advisor and videogame advocate Mark DeLoura as the Executive Director of Innovation & Growth, a new leadership role to ensure GDC's strategy, programming and presence are future-facing and deeply connected to the industry it serves. Heading into its 40th edition, GDC is transforming into a Festival of Gaming, expanding its scope to represent the full game-making ecosystem and better meet the needs of the contemporary games industry. GDC 2026 will return to the Moscone Center in San Francisco next year, Monday, March 9 to Friday, March 13, 2026. Mark's career has been defined by an intellectual curiosity and an exploration of the endless possibilities of game development around education, inclusion, civic engagement and the public good. In his more than three decades experience he has held such wide-ranging titles as journalist, technical director, vice president of technology, consultant, advocate and senior advisor. On the console side, Mark helped launch iconic game platforms like Nintendo 64, GameCube and PlayStation 3. He has authored programming books and served as the editor-in-chief of Game Developer Magazine, helping generations better understand game technology. Mark's history with GDC goes as far back as helping oversee the original event's transition from the Computer Game Developers Conference (1988-1999) into the inclusive, globally relevant platform now known as the Game Developers Conference, and he has served as an advisor for the event for more than 10 years. Mark's technical and academic understanding of game development culminated in his role as the Senior Advisor for Digital Media at the White House Office of Science and Technology Policy under President Obama. In his ongoing advocacy of the positive influence of gaming technology, Mark's new role as Executive Director of Innovation & Growth of GDC puts him center stage in an exciting effort to shape the next chapter of GDC. In its 40th edition, the new GDC will be a reimagined platform that reflects the entire game-making ecosystem, and Mark's vision, grounded in years of industry insight, will help to shape this broader strategy and ensure it delivers meaningful value to every corner of the community. 'Mark has been a longtime member of the GDC family,' said Nina Brown, Vice President of Gaming at Informa Festivals. 'We could not have a better leader joining to help change the game as GDC becomes an inclusive Festival of Gaming to better serve the industry we all love. He is among the rare few that have the holistic perspective of the rapidly evolving industry from the inside out.' "GDC has always been a home for people who care deeply about making games and now it's transforming into something even more ambitious!" said Mark DeLoura, GDC's Executive Director of Innovation & Growth. 'It's incredibly exciting to step into this role to ensure that GDC remains connected to the community while expanding to serve everyone who is shaping the future of games.' For more details on the Game Developers Conference, please visit the GDC's official website, or subscribe to regular updates via Facebook, X or BlueSky. Official photos are available via the Official GDC Flickr account: About GDC The Game Developers Conference® (GDC) is the world's largest professional game industry event with market-defining content for programmers, artists, producers, game designers, audio professionals, business decision makers and others involved in the development of interactive games and immersive experiences. GDC brings together the global game development community year-round through events and digital media, including the networking meet-up's, GDC Vault, Independent Games Festival and Summit, and the Game Developers Choice Awards. GDC is organized by Informa PLC, a leading B2B information services group and the largest B2B Events organizer in the world. To learn more and for the latest news and information visit
Business Wire
18 minutes ago
- Business Wire
KBRA Releases Research – Private Credit: Q2 2025 Middle Market Borrower Surveillance Compendium—Waiting for Godot
NEW YORK--(BUSINESS WIRE)--KBRA releases its Q2 2025 Middle Market Borrower Surveillance Compendium. Private credit may well be in a 'Waiting for Godot' moment—marked by growing anticipation of some unknown reckoning that continues to be deferred. As the industry continues to adapt to various market uncertainties, KBRA notes signs of improving credit quality for some borrowers, while still observing a subset of borrowers that face maturities over the next two years without the growth their sponsors and borrowers had expected. In this quarterly report, we review the nearly 2,400 KBRA assessments completed for 2,115 unique global middle market (MM)-sponsored borrowers over the last 12 months (LTM) ending June 30, 2025. We examine key trends shaping credit quality by company size and sector, outline the shifts that have taken place in our portfolio during 1H 2025, and share some of our expectations heading to year-end. We also provide new data on 371 surveillance assessments and 251 new assessments conducted in Q2 2025. The companies assessed in the LTM period held over $1 trillion in cumulative borrowings. Over that period, we have reviewed over 200 companies with direct loans over $1 billion, which represents a substantial portion of the private loans in the upper MM. We also assessed nearly 200 companies with loans under $50 million, demonstrating the breadth of our coverage universe. We believe this expansive view offers perspectives on the evolving risks and the effectiveness of direct lenders' responses amid uncertain times. While pockets of underperformance are inevitable in any investment category—especially leveraged loans—we continue to see little evidence of widespread credit stress despite elevated rates and policy uncertainty (see Private Credit: A Source of Systemic Strength). Key Takeaways Revenue and EBITDA performance for this portfolio of obligors, which hold over $1 trillion in debt, broke the trend from prior LTM periods. Instead of both metrics slowing, the revenue-compounded annual growth rate (CAGR) stood firm at 14% while the EBITDA CAGR accelerated 100 basis points to 31%, when compared to Q1. All else equal, several other key metrics appear to be setting the scene for a positive finish to what has been a turbulent start to 2025. Continued positive performance from the largest sectors coupled with ongoing sector rotation could help explain the shift in performance trajectory seen in Q2. Three sectors where private credit has the greatest exposure—Commercial and Professional Services, Software, and Health Care Services and Technology—continue to drive the performance of the overall portfolio due to their significant growth rates. Other sectors exhibiting strong performance also gained a larger share by count as compared to the underperforming portion of the portfolio. KBRA recorded two payment defaults during the Q2 2025 surveillance cycle, representing 1.1% of the quarter's reviewed portfolio—the lowest total observed in recent periods. However, a performance divide appears to be emerging between services-oriented businesses and goods-producing companies, with the former showing comparatively stronger results at the median. Looking ahead, we anticipate greater distress among sectors focused on manufacturing, retail, and distribution during the second half of the year. Moreover, with 27% of companies that we assessed in the ccc category and the amount of maturities pending between 2025 and 2028, the risk of additional defaults remains elevated in the absence of sponsor or lender intervention. For the first time since KBRA began tracking the proportion of companies with improving versus deteriorating interest coverage ratios (ICRs), the share with strengthening metrics has taken a decisive lead. That said, the percentage of companies with an ICR below 1.0x has remained relatively flat, holding at approximately one-quarter of the portfolio over the past few periods. The upgrade-to-downgrade ratio for the 371 companies assessed in Q2 showed notable improvement compared to the prior three quarters. This coincided with a shift in the composition or surveillance and new assessment scores, which were more heavily weighted toward the b- and higher categories rather than ccc+ and lower, as seen in past quarters. While both developments are credit-positives, they pertain to only one quarter period and a small segment of the portfolio. As such, a few more quarters of data are needed before we can draw any firm conclusions. Median leverage for MM borrowers in this higher interest rate environment appears to have reached a floor at 6.1x. Despite continued EBITDA expansion, direct lenders are fueling some of that growth with additional debt for add-on acquisitions and other growth initiatives—keeping median leverage consistently at this level over the past four quarters. Click here to view the report. About KBRA KBRA, one of the major credit rating agencies, is registered in the U.S., EU, and the UK. KBRA is recognized as a Qualified Rating Agency in Taiwan, and is also a Designated Rating Organization for structured finance ratings in Canada. As a full-service credit rating agency, investors can use KBRA ratings for regulatory capital purposes in multiple jurisdictions. Doc ID: 1010497
